Curation-free biomodules mechanisms in prostate cancer predict recurrent disease

BMC Medical Genomics

Volumn 6, Issue SUPPL2, 2013, Pages

  Chen, James L ^a,b   Hsu, Alexander ^a,c   Yang, Xinan ^a   Li, Jianrong ^c   Lee, Younghee ^a   Parinandi, Gurunadh ^c   Li, Haiquan ^c   Lussier, Yves A ^a,c,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; AUTOMATION; CANCER PROGNOSIS; CANCER RECURRENCE; CLASSIFIER; FUNCTIONAL ANALYSIS OF INDIVIDUAL MICROARRAY EXPRESSION ALGORITHM; GENE EXPRESSION; GENOMICS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GENE;

COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84877319881     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-S2-S4     Document Type: Article

References (28)

1. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. Chen JL, Li J, Stadler WM, Lussier YA, Journal of the American Medical Informatics Association 2011 18 4 392 402 10.1136/amiajnl-2011-000178 21672909
2. Sorting Out Breast-Cancer Gene Signatures. Massagué J, New England Journal of Medicine 2007 356 3 294 297 10.1056/NEJMe068292 17229957 (Pubitemid 46143233)
3. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, et al. BMC medical genomics 2010 3 8 10.1186/1755-8794-3-8 20233430
4. Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. Lussier YA, Stadler WM, Chen JL, J Am Med Inform Assoc 2012 19 2 156 160 10.1136/amiajnl-2011-000419 22101905
5. Network-based classification of breast cancer metastasis. Chuang HY, Lee E, Liu YT, Lee D, Ideker T, Mol Syst Biol 2007 3 140 17940530
6. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. Nature 2006 439 7074 353 357 10.1038/nature04296 16273092 (Pubitemid 43128862)
7. Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. Abraham G, Kowalczyk A, Loi S, Haviv I, Zobel J, BMC bioinformatics 2010 11 277 10.1186/1471-2105-11-277 20500821
8. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, et al. Journal of the National Cancer Institute 2011 103 3 264 272 10.1093/jnci/djq524 21191116
9. Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer. Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, Cohen EEW, Xing HR, Lussier YA, PLoS Comput Biol 2012 8 1 1002350 10.1371/journal.pcbi. 1002350 22291585
10. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Proceedings of the National Academy of Sciences of the United States of America 2005 102 43 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
11. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. J Clin Oncol 2004 22 14 2790 2799 10.1200/JCO.2004.05.158 15254046 (Pubitemid 41079896)
12. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S, Cancer research 2008 68 3 927 936 10.1158/0008-5472.CAN-07-2608 18245496 (Pubitemid 351206772)
13. Integrative Genomic Profiling of Human Prostate Cancer. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Cancer Cell 2010 18 1 11 22 10.1016/j.ccr.2010.05.026 20579941
14. Gene expression profiling predicts clinical outcome of prostate cancer. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL, The Journal of clinical investigation 2004 113 6 913 923 15067324 (Pubitemid 38544150)
15. A module map showing conditional activity of expression modules in cancer. Segal E, Friedman N, Koller D, Regev A, Nat Genet 2004 36 10 1090 1098 10.1038/ng1434 15448693
16. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Huang da W, Sherman BT, Lempicki RA, Nat Protoc 2009 4 1 44 57 19131956
17. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH, Urology 2009 74 4 878 883 10.1016/j.urology.2009.03.004 19476985
18. Stat3 Promotes Metastatic Progression of Prostate Cancer. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, et al. The American Journal of Pathology 2008 172 6 1717 1728 10.2353/ajpath.2008.071054 18483213 (Pubitemid 351793362)
19. The chondramides: cytostatic agents from myxobacteria acting on the actin cytoskeleton. Sasse F, Kunze B, Gronewold TM, Reichenbach H, Journal of the National Cancer Institute 1998 90 20 1559 1563 10.1093/jnci/90.20.1559 9790549 (Pubitemid 28535721)
20. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstadter F, et al. Clin Cancer Res 2011 17 5 1111 1121 10.1158/1078-0432.CCR- 10-0081 21220479
21. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Konishi N, Shimada K, Nakamura M, Ishida E, Ota I, Tanaka N, Fujimoto K, Clin Cancer Res 2008 14 14 4408 4416 10.1158/1078-0432. CCR-07-4120 18628455
22. Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression. Chen JL, Li J, Kiriluk KJ, Rosen AM, Paner GP, Antic T, Lussier YA, Vander Griend DJ, Clinical Cancer Research 2012 18 16 4291 4302 10.1158/1078-0432.CCR-12-0373 22723371
23. Identifying disease genes and module biomarkers by differential interactions. Liu X, Liu Z-P, Zhao X-M, Chen L, Journal of the American Medical Informatics Association 2012 19 2 241 248 10.1136/amiajnl-2011-000658 22190040
24. Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P, Shen Q, Nemenman I, Basso K, Margolin AA, et al. Nat Biotechnol 2009 27 9 829 839 10.1038/nbt.1563 19741643
25. ExprTarget: An Integrative Approach to Predicting Human MicroRNA Targets. Gamazon ER, Im H-K, Duan S, Lussier YA, Cox NJ, Dolan ME, Zhang W, PLoS ONE 2010 5 10 13534 10.1371/journal.pone.0013534 20975837
26. Network Modeling Identifies Molecular Functions Targeted by miR-204 to Suppress Head and Neck Tumor Metastasis. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, Li J, Hasina R, Cheng C, Lingen MW, et al. PLoS Comput Biol 2010 6 4 1000730 10.1371/journal.pcbi.1000730 20369013
27. Gene expression profiling predicts clinical outcome of breast cancer. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Nature 2002 415 6871 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
28. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. New England Journal of Medicine 2004 351 27 2817 2826 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)